Ubicación: Global + English
Global Global Algérie Français Algeria English Angola Português Angola English Argentina Español Argentina English Australia English Austria Deutsch Austria English Azerbaijan English Azerbaijan Русский Bahrain English Bangladesh English Belgium English Belgium Français Belgium Nederlands Brazil Português Brazil English Bulgaria български Bulgaria English Cameroon English Cameroon Français Canada English Canada Français Chile Español Chile English China 中文 China 日本語 China English Colombia Español Colombia English Croatia English Czech Republic Čeština Czech Republic English Denmark English Djibouti English Ecuador Español Ecuador English Egypt English Estonia English Ethiopia English Finland Suomi Finland English France Français France English Georgia English Georgia Русский Germany Deutsch Germany English Ghana English Greece Ελληνικά Greece English Guatemala Español Guatemala English Hong Kong, China English Hong Kong, China 中文 Hungary Magyar Hungary English India English Indonesia English Iraq English Ireland English Italy Italiano Italy English Ivory Coast Français Ivory Coast English Japan 日本語 Japan English Jordan English Kazakhstan Русский Kazakhstan English Kenya English Kuwait English Kyrgyzstan Русский Kyrgyzstan English Latvia English Lithuania English Malaysia English Mauritius English Mauritius français (Maurice) Mexico Español Mexico English Moldova Română Moldova English Mongolia English Morocco English Morocco Français Mozambique Português Mozambique English Netherlands Nederlands Netherlands English New Zealand English Nigeria English Norway English Oman English Pakistan English Paraguay Español Paraguay English Peru Español Peru English Philippines English Poland Polski Poland English Portugal Português Portugal English Qatar English Republic of Korea 한국어 Republic of Korea English Romania Română Romania English Saudi Arabia English Serbia Српски Serbia English Singapore English Slovakia English Slovenia English South Africa English Spain English Spain Español Sri Lanka English Sweden English Switzerland Deutsch Switzerland Français Switzerland Italiano Switzerland English Tanzania English Thailand ไทย Thailand English Togo English Togo Français Tunisia English Tunisia Français Türkiye Türkçe Türkiye English Turkmenistan Русский Turkmenistan English Ukraine Українська Ukraine English United Arab Emirates English United Kingdom English Uruguay Español Uruguay English USA English Uzbekistan English Uzbekistan Русский Vietnam Tiếng Việt Vietnam English

Anti-Inflammatory Activity Evaluation of Traditional Chinese Medicine: Technical Framework, Testing

Anti-inflammatory activity evaluation of Traditional Chinese Medicine (TCM) is a systematic testing process that combines in vitro cell-based assays, biochemical enzyme assays, and in vivo animal models to quantify the therapeutic potential of herbal extracts and active compounds. By measuring key inflammatory mediators such as nitric oxide, prostaglandins, and pro-inflammatory cytokines, alongside signaling pathway analysis, accredited laboratories provide scientifically validated data supporting TCM drug development, quality control, and product claims. This article outlines the complete technical framework, testing samples, methods, standards, and frequently asked questions related to TCM anti-inflammatory activity assessment.

Technical Overview

Inflammation is a protective biological response involving immune cells, inflammatory mediators, and signaling cascades such as NF-κB, MAPK, JAK/STAT, and the NLRP3 inflammasome. Chronic or dysregulated inflammation is implicated in arthritis, metabolic syndrome, cardiovascular disease, inflammatory bowel disease, and neurodegenerative disorders. Traditional Chinese Medicine (TCM) has long been used to treat inflammatory conditions, and modern pharmacological studies have confirmed that many herbs—including Scutellaria baicalensis, Glycyrrhiza uralensis, Salvia miltiorrhiza, Curcuma longa, Coptis chinensis, and Astragalus membranaceus—contain flavonoids, alkaloids, terpenoids, phenolic acids, and polysaccharides with demonstrable anti-inflammatory activity.

Anti-inflammatory activity evaluation of TCM is a multi-tiered assessment framework that integrates four dimensions: chemical characterization (HPLC fingerprinting and marker compound quantification in accordance with the Chinese Pharmacopoeia and relevant GB standards), in vitro biochemical and cell-based screening, in vivo pharmacodynamic validation in animal models, and mechanistic investigation of molecular targets. Quantitative endpoints include IC50 values, inhibition percentages, ED50 values, and dose-response relationships, all generated under ISO/IEC 17025-aligned laboratory quality systems and, where animal studies are involved, in compliance with OECD principles of Good Laboratory Practice (GLP) and institutional animal ethics requirements.

Testing Samples

Herbal Extracts and Fractions

Crude and refined extracts obtained through aqueous decoction, ethanol reflux, ultrasonic-assisted extraction, or supercritical CO2 extraction, along with solvent-partitioned fractions (petroleum ether, ethyl acetate, n-butanol, and aqueous fractions). These samples are typically profiled for total flavonoid, polyphenol, and alkaloid content before biological testing.

Single Active Compounds and Marker Substances

Purified phytochemicals such as baicalin, baicalein, glycyrrhizin, berberine, curcumin, triptolide, salvianolic acid B, astragaloside IV, emodin, and paeoniflorin. Compound testing establishes reference IC50 values and supports structure-activity relationship (SAR) studies.

TCM Formulations, Decoctions, and Granules

Multi-herb prescriptions, concentrated granules, classic formulas, and proprietary medicines. Multi-component samples require fingerprint consistency assessment before activity testing to ensure that observed effects are attributable to a defined chemical profile.

Polysaccharides and Macromolecular Constituents

Water-soluble polysaccharides from herbs such as Astragalus, Ganoderma, and Angelica, evaluated primarily through complement pathway, macrophage modulation, and intestinal inflammation models.

Finished Products

Health foods, dietary supplements, botanical drugs, topical formulations, and cosmetic ingredients containing TCM-derived actives, tested to substantiate label claims and support regulatory submissions.

Testing Items

Anti-inflammatory evaluation encompasses a structured set of measurable endpoints:

  • Nitric oxide (NO) production inhibition in LPS-stimulated macrophages, quantified by the Griess reaction
  • Prostaglandin E2 (PGE2) levels and cyclooxygenase (COX-1/COX-2) inhibitory activity
  • Pro-inflammatory cytokine secretion: TNF-α, IL-1β, IL-6, IL-8, MCP-1, and IL-12
  • Anti-inflammatory cytokine modulation: IL-10 and TGF-β1
  • Enzymatic targets: inducible nitric oxide synthase (iNOS), 5-lipoxygenase (5-LOX), and phospholipase A2
  • Signaling pathway analysis: NF-κB p65 nuclear translocation, IκBα phosphorylation and degradation, p38/JNK/ERK MAPK phosphorylation, and NLRP3 inflammasome activation
  • Gene expression profiling of inflammatory mediators by RT-qPCR
  • In vivo endpoints: paw edema rate, ear edema inhibition, granuloma weight, arthritis index, vascular permeability, and inflammatory cell infiltration scores
  • Safety co-endpoints: cell viability (MTT/CCK-8), acute oral toxicity per OECD Test Guideline 423, and zebrafish embryo toxicity aligned with ISO 15088

Testing Methods

In Vitro Cell-Based Assays

The cornerstone of TCM anti-inflammatory screening is the lipopolysaccharide (LPS)-stimulated RAW264.7 murine macrophage model, supplemented by THP-1 human monocyte-derived macrophages and primary cells for confirmatory studies. Cells are pre-treated with graded concentrations of the test sample, stimulated with LPS, and assessed for NO release (Griess reagent spectrophotometry), cytokine secretion (sandwich ELISA), protein expression (Western blotting and immunofluorescence), and mRNA levels (RT-qPCR). Parallel cytotoxicity testing ensures that apparent inhibition is not an artifact of reduced cell viability.

Biochemical and Enzymatic Assays

Cell-free assays include colorimetric and fluorometric COX-1/COX-2 inhibition kits, 5-LOX activity assays, and free radical scavenging assays (DPPH, ABTS, and FRAP) to evaluate the antioxidant-inflammatory interplay of phenolic-rich extracts. Molecular docking and network pharmacology are applied to predict target engagement and guide mechanistic hypothesis generation.

Chemical Characterization and Method Validation

HPLC, UHPLC-MS/MS, and GC-MS fingerprinting quantify marker compounds in accordance with Chinese Pharmacopoeia monographs and applicable GB/T standards. Analytical methods are validated for specificity, linearity, accuracy, precision, and robustness in line with ICH Q2(R2) guidelines to ensure that biological activity data are linked to a reproducible chemical composition.

In Vivo Pharmacodynamic Models

Standard rodent models are used to validate in vitro findings under GLP-compliant, ethics-approved protocols:

  • Carrageenan-induced paw edema in rats (acute inflammation, two-phase response)
  • Xylene-induced ear edema in mice (acute vascular permeability)
  • Cotton pellet-induced granuloma (chronic proliferative inflammation)
  • Complete Freund's Adjuvant (CFA)-induced arthritis (autoimmune joint inflammation)
  • Zymosan-induced air pouch (exudate cytokine profiling)
  • TNBS- or DSS-induced colitis (intestinal inflammation)
  • Acetic acid-induced writhing and hot-plate tests (inflammation-associated analgesia)

Positive controls such as dexamethasone, indomethacin, and celecoxib are run in parallel, and results are reported as percentage inhibition, ED50, and statistical significance versus model controls.

Quality and Compliance Framework

Studies are conducted in accredited third-party laboratories operating under ISO/IEC 17025 quality management systems, with animal work performed in AAALAC-accredited facilities where applicable, following the 3Rs principle (replacement, reduction, refinement) and national laboratory animal welfare regulations.

Applications

Anti-inflammatory activity evaluation data serve multiple purposes across the TCM value chain:

  • Drug discovery and lead optimization: Screening herbal compound libraries, prioritizing bioactive fractions, and supporting structure-activity studies of single phytochemicals.
  • Mechanism-of-action elucidation: Defining interactions with NF-κB, MAPK, and NLRP3 pathways for publication, patent filing, and regulatory dossiers.
  • Quality control and batch consistency: Linking HPLC fingerprints to biological potency to establish activity-based quality markers (Q-markers) for herbal extracts.
  • Functional food and supplement claims: Providing scientific substantiation for "helps modulate inflammatory response" type claims in health food registrations.
  • Cosmetic ingredient validation: Supporting soothing and anti-redness claims for TCM-derived cosmetic actives under ISO-compliant safety assessment frameworks.
  • Regulatory submissions: Generating pharmacodynamic study packages for traditional medicine registrations, import/export documentation, and clinical trial applications.

FAQ

What is the recommended screening strategy for a new TCM extract?

A tiered approach is standard: begin with chemical fingerprinting and the LPS-stimulated RAW264.7 NO inhibition assay with parallel cytotoxicity testing, proceed to cytokine ELISA and pathway confirmation for active samples, and conclude with one or two in vivo edema models selected according to the intended therapeutic indication.

How long does a complete evaluation typically take?

In vitro screening (NO, cytokines, Western blot) generally requires 2 to 4 weeks, chemical characterization 1 to 2 weeks, and in vivo pharmacodynamic studies 4 to 8 weeks depending on the model; chronic arthritis and colitis models may extend to 12 weeks including acclimatization and histopathology.

What sample concentrations are typically tested?

In vitro assays commonly span 6.25 to 200 μg/mL for extracts and 0.1 to 100 μM for pure compounds, with solubility and cytotoxicity limits defining the upper boundary. In vivo dosing typically ranges from 50 to 400 mg/kg for extracts, benchmarked against positive-control drugs.

How is anti-inflammatory potency reported?

Results are expressed as IC50 (concentration inhibiting 50% of mediator release), percentage inhibition at defined doses, ED50 in animal models, and selectivity indices such as COX-2/COX-1 ratios, always accompanied by confidence intervals and statistical analysis.

Are in vivo studies mandatory?

For basic screening and claim substantiation, in vitro data may suffice; however, pharmacodynamic validation in at least one animal model is generally expected for new drug applications and is strongly recommended for mechanistic publications and patent support.

Can multi-herb formulas be meaningfully evaluated?

Yes. Formulas are first standardized by multi-component HPLC fingerprinting to confirm batch consistency, after which the full evaluation cascade is applied. Network pharmacology is frequently used to rationalize synergistic interactions among constituent herbs before experimental confirmation.

Why Choose ZKGX?

  • State-of-the-art analytical equipment
  • Highly qualified scientific team
  • Fast turnaround time
  • Competitive pricing